PIK3CA and cancer: Over ten different PI3K inhibitors have been tested in various cancer cells, i.e. breast cancer, lung cancer, colorectal cancer cells, etc. Cells with PIK3CA mutation have been demonstrated to be more susceptible to the inhibitors than those without [12], [19]–[22].